Focus on the international biomedicine frontier race track: the type 2 diabetes living biological drug pipeline was officially launched in Zhangjiang Pharmaceutical Valley

On October 8, under the witness of the General Health Professional Committee of Shanghai Modern Service Industry Federation, Zhangjiang Living diabetes II (T2D) Living Biological Drug (LBP) pipeline of Zhangjiang Living Biological Drug Research and Development Center was officially launched. Jian Danian, Vice President of Shanghai Modern Service Industry Federation, stated that the federation will continue to closely adhere to Shanghai's modern industrial system and introduce more high-level technology enterprises to Pudong and Zhangjiang

On October 8, under the witness of the General Health Professional Committee of Shanghai Modern Service Industry Federation, Zhangjiang Living diabetes II (T2D) Living Biological Drug (LBP) pipeline of Zhangjiang Living Biological Drug Research and Development Center was officially launched. Jian Danian, Vice President of Shanghai Modern Service Industry Federation, stated that the federation will continue to closely adhere to Shanghai's modern industrial system and introduce more high-level technology enterprises to Pudong and Zhangjiang.

This is the earliest established comprehensive national science center. Over the past 30 years, 24000 enterprises, over 1800 high-tech enterprises, and 179 foreign-funded research and development centers have emerged from the fertile soil of Zhangjiang Science City. At present, there are a series of national strategic overlapping opportunities, including the National Science and Technology Innovation Center, Independent Innovation Demonstration Zone, Shanghai Pilot Free Trade Zone, Pudong Leading Zone, and High Level Talent Highland.

Why does Zhangjiang focus on diabetes drug pipeline this time? What else can the biopharmaceutical industry do in Zhangjiang? Experts are discussing new drug research and development and entrepreneurship ecology in this regard.

Creating a "Tropical Rainforest" style venture capital ecosystem in Zhangjiang

It is reported that the Zhangjiang Pharmaceutical Valley platform was established in 2004 and was recognized by the "National High tech Entrepreneurship Service Center" of the Ministry of Science and Technology at the end of 2007 (a national level biopharmaceutical professional incubator). At the same time, it was recognized by the national qualification assessment laboratory. Zhangjiang Pharmaceutical Valley relies on incubation services, with professional technical services and investment and financing services as its pillars, focusing on professional incubation and cultivation at the front end of the new drug research and development production chain. For over 30 years, Zhangjiang, located in the Pudong New Area, has long been the preferred starting point for overseas returnees, "said Yuan Tao, Chairman of Shanghai (Zhangjiang) Group Co., Ltd. Firstly, Shanghai itself is an international city; Secondly, Zhangjiang has a large number of multinational corporations and research and development centers, with spillover effects superimposed on industrial development, naturally forming an entrepreneurial ecosystem. Especially in recent years, the country has attached great importance to the development of high-tech, and biopharmaceuticals, artificial intelligence, and integrated circuits have become the three major hardcore industries in Shanghai Especially in the field of biopharmaceuticals, Zhangjiang is providing opportunities for small and medium-sized enterprises.

Ling Gang, Chief Engineer of the Pudong New Area Science and Technology Commission, introduced that the true innovation of Chinese drugs began around 2014 and has entered an acceleration period in the past decade. At present, the number of innovative drugs in China accounts for about 23.7% of the global market, undoubtedly belonging to the second largest tier in the short term. It is revealed that Zhangjiang, for example, will focus on drug research and development in areas such as cells and genes, and will make every effort to create a "tropical rainforest style" venture capital ecosystem from industrial positioning, policy support, service platform, and other aspects.

He vividly compares it to the "Six Grand Canal Industries" - by 2025, Pudong aims to cultivate and form six hard core industrial clusters with a scale of "hundreds of billions", among which "innovative drugs" will become a 200 billion yuan industrial cluster. Next, we will invest more support in areas such as talent policies and the development of the traditional Chinese medicine industry

Ge Guangbo, Executive Vice President and Chief Consultant of Pharmacy at the Cross disciplinary Research Institute of Shanghai University of Traditional Chinese Medicine, mentioned that many components in traditional Chinese medicine are difficult to absorb into the bloodstream. Therefore, in many cases, their clinical efficacy is achieved by regulating the gut microbiota, thereby generating endogenous metabolism to achieve improvement. This is a very promising direction. In the multi team focus of universities, enterprises, and medical institutions, we hope to combine production, learning, and research closely to ultimately lead basic research to clinical practice and develop safe and effective Chinese new drugs

Building a long-term pipeline platform for gut microbiomics

The research and development of living biological drugs (LBP) for type 2 diabetes (T2D) launched this time is a new attempt of Zhangjiang enterprises. Chen Weijie, chairman of Shanghai Lishan Biomedical Co., Ltd., introduced that according to the latest progress of the research team, a live biological drug targeting intestinal bacteria for insulin resistance subtype of type 2 diabetes will be launched, and it is planned to enter phase 1 clinical practice in 2025. It is reported that this innovative living biological drug is expected to become the first-line drug for specific subgroups of type 2 diabetes and change the current sugar control route of type 2 diabetes. At the same time, more than 700 strains of characteristic strains of traditional Chinese medicine will be screened and isolated by 2026, and the gene jigsaw and culture storage of new strains will be completed.

It is reported that gut microbiome is currently a new track in international biopharmaceutical research, breaking through the limitations of traditional biopharmaceuticals. Through deep learning of big data through interdisciplinary interdisciplinary integration and artificial intelligence, it explores the boundaries of innovative biopharmaceuticals. "Especially in the treatment of inflammatory bowel disease, infection and metabolic diseases, living bacteria therapy has opened a new therapeutic revolution. This therapy neutralizes the inflammatory and metabolic signals generated by pathogens by introducing beneficial microorganisms into the human flora affected by the disease." He revealed that although the project is currently known as the pipeline of type 2 diabetes, it will take this platform in the future to enrich the flora and basic research theory, Looking forward to the continuous generation of new drugs targeting various immune regulatory disorders as the ultimate energy source.

The Great Health Special Committee will be built into a platform that serves enterprises, universities, members, and society, connecting upstream and downstream industries in the field of great health, providing support for cross-border integration, and allowing more such achievements to truly take root, "said Fan Jincheng, the chairman of the Great Health Special Committee.

Editor in Chief: Gu Yong

Source: Author: Huang Yangzi

Disclaimer: The content of this article is sourced from the internet. The copyright of the text, images, and other materials belongs to the original author. The platform reprints the materials for the purpose of conveying more information. The content of the article is for reference and learning only, and should not be used for commercial purposes. If it infringes on your legitimate rights and interests, please contact us promptly and we will handle it as soon as possible! We respect copyright and are committed to protecting it. Thank you for sharing.(Email:[email protected])